Lubrication Behavior of Fullerene-Coated Nanoparticles on Rough Surfaces by Guangchao Han (1453198)

Subjects:

Lubrication Behavior of Fullerene-Coated Nanoparticles on Rough Surfaces by Guangchao Han (1453198)

Subjects:

Primer sequences for quantitative RT-PCR. by Li Li (14993)

“…Compared with the Model Group, the red blood cell (RBC) count, hemoglobin (HB) content and hematokrit (HCT) of rats blood routine in the Model+high doses of CBMHL Group (Model+H-CBMHL Group) increased significantly (<i>P</i> < 0.05). Serum erythropoietin (EPO) and glutathione (GSH) levels increased significantly (<i>P</i> < 0.05), while serum creatinine (Cr) levels decreased significantly(<i>P</i> < 0.05). …”

The freeze-drying curve of liposomes. by Li Li (14993)

“…Compared with the Model Group, the red blood cell (RBC) count, hemoglobin (HB) content and hematokrit (HCT) of rats blood routine in the Model+high doses of CBMHL Group (Model+H-CBMHL Group) increased significantly (<i>P</i> < 0.05). Serum erythropoietin (EPO) and glutathione (GSH) levels increased significantly (<i>P</i> < 0.05), while serum creatinine (Cr) levels decreased significantly(<i>P</i> < 0.05). …”

Certificate for laboratory animal. by Li Li (14993)

“…Compared with the Model Group, the red blood cell (RBC) count, hemoglobin (HB) content and hematokrit (HCT) of rats blood routine in the Model+high doses of CBMHL Group (Model+H-CBMHL Group) increased significantly (<i>P</i> < 0.05). Serum erythropoietin (EPO) and glutathione (GSH) levels increased significantly (<i>P</i> < 0.05), while serum creatinine (Cr) levels decreased significantly(<i>P</i> < 0.05). …”

Sociodemographic characteristics of participants at baseline, overall and by age group. by Chelsea S. Lutz (16001569)

Subjects:

Symptoms self-reported and/or documented in the electronic health record during the acute COVID-19 illness, by hospitalization status and age group. by Chelsea S. Lutz (16001569)

Subjects:

Average percent relative abundance of top 10 most abundance species of healthy control and stroke patient groups. by Duangnapa Roongpiboonsopit (12829198)

Subjects:

Sociodemographic and clinical characteristics associated with PCC at three months post-acute illness among adults enrolled during Omicron predominance. by Chelsea S. Lutz (16001569)

Subjects:

Rarefaction curves of quality reads per sample at (A) phylum and (B) genus level operational taxonomic units (OTUs), in patient and control samples. by Duangnapa Roongpiboonsopit (12829198)

Subjects:

Alpha-diversity analysis at genus level including operational taxonomic unit (OTUs), Chao richness and Shannon diversity indices. by Duangnapa Roongpiboonsopit (12829198)

Subjects:

Clinical characteristics of patients and controls. by Duangnapa Roongpiboonsopit (12829198)

Subjects:

(A) Beta-diversity non-metric multidimensional scaling (NMDS) analysis at genus level, and (B) LEfSe for bacterial species biomarkers representing control vs. stroke groups. by Duangnapa Roongpiboonsopit (12829198)

Subjects:

Microbial metabolic potentials categorized according to KEGG (A) level 1 and (B) level 2, representing control vs. stroke groups. by Duangnapa Roongpiboonsopit (12829198)

Subjects:

Microbiota compositions in percent relative abundance between healthy control and stroke patient individuals (the average microbiota between groups were displayed on the rightmost... by Duangnapa Roongpiboonsopit (12829198)

Subjects:

Manifestations of Post-COVID-19 Conditions (PCC) three months post-acute illness, among those with PCC, by age group^a. by Chelsea S. Lutz (16001569)

Subjects:

Clinical outcomes and COVID-19 treatment during acute illness, by hospitalization status and age group. by Chelsea S. Lutz (16001569)

Subjects:

Study selection criteria. by Filip Stanicic (17808254)

“…Phase II/III trials consistently reported significantly greater CAPS improvement with MDMA-AT vs. placebo with therapy (PT) after two or three interventional sessions. …”

PICOS criteria for the SLR. by Filip Stanicic (17808254)

“…Phase II/III trials consistently reported significantly greater CAPS improvement with MDMA-AT vs. placebo with therapy (PT) after two or three interventional sessions. …”

PRISMA flow chart. by Filip Stanicic (17808254)

“…Phase II/III trials consistently reported significantly greater CAPS improvement with MDMA-AT vs. placebo with therapy (PT) after two or three interventional sessions. …”